A case of neuroleptic malignant syndrome (NMS) in a patient with Parkinson's disease (PD) is presented. The syndrome was precipitated by the atypical antipsychotic, ziprasidone. The challenge of recognizing NMS in a patient with underlying parkinsonian symptoms, where prominent symptom overlap can occur, is discussed.
All Science Journal Classification (ASJC) codes
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)